

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**ANNOUNCEMENT IN RELATION TO THE RECEIPT OF THE NOTICE OF
REVIEW OPINION FROM THE SHANGHAI STOCK EXCHANGE FOR
THE PROPOSED ISSUANCE**

References are made to the announcement and circular (the “**Circular**”) dated 7 March 2022, the poll results announcement dated 6 April 2022, and the announcement dated 14 June 2022 of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”), in relation to the Proposed Issuance. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

On 15 September 2022, the Company received a notice (the “**Notice**”) from the Listing Review Center* (上市審核中心) of the STAR Market of the Shanghai Stock Exchange regarding the review of the Proposed Issuance. According to the Notice, the application for the Proposed Issuance fulfills the conditions for issuance and listing, and the information disclosure requirements. The Shanghai Stock Exchange will submit the application documents (registration version) to the CSRC for registration upon provision of the same by the Company.

The Proposed Issuance is subject to the approval for registration of the CSRC. There are uncertainties as to whether the CSRC will issue the approval for registration and the timing thereof. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 16 September 2022

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* *For identification purpose only*